Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products-Reference-Cited by-同舟云学术

Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products

Published:2015-02-26 Issue:3 Volume:17 Page:758-768
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Hendeles Leslie,Daley-Yates Peter T.,Hermann Robert,De Backer Jan,Dissanayake Sanjeeva,Horhota Stephen T.

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-015-9735-7.pdf

Reference37 articles.

1. Daley-Yates P. Biomarkers of the anti-inflammatory effects in the airways and the evaluation of therapeutic equivalence. IPAC-RS/UF Inhalation Conference in Orlando. 2014. http://www.cvent.com/events/orlando-inhalation-conference-approaches-in-international-regulation/agenda-8a749091c2c741228907ca5c70b619eb.aspx . Accessed 13 Nov 2014.

2. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–15.

3. Daley-Yates PT, Austin DJ, Bentley JH. Exhaled nitric oxide (eNO) versus adenosine-5′-monophosphate (AMP) challenge for demonstrating dose response to inhaled corticosteroid (abstract). Am J Respir Crit Care Med. 2013;187:A1926.

4. Singh D, Fairwood J, Murdoch R, Weeks A, Russell P, Roy K, et al. The reproducibility of adenosine monophosphate bronchial challenges in mind, steroid-naive asthmatics. Br J Clin Pharmacol. 2008;66:261–5.

5. Austin DJ, Daley-Yates PT. Evaluation of exhaled nitric oxide (eNO) as a tool for bioequivalence testing of inhaled corticosteroids (abstract). Am J Respir Crit Care Med. 2013;187:A1927.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case Report: Can Inhaled Adenosine Attenuate COVID-19?;Frontiers in Pharmacology;2021-08-09

2. Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process;Pharmaceutics;2021-07-09

3. A Dose-Response Study Examining the Use of Methacholine Challenge to Demonstrate Local Therapeutic Equivalence of the Salmeterol Component of Generic Inhaled Fluticasone Propionate/Salmeterol Combination Products;Journal of Aerosol Medicine and Pulmonary Drug Delivery;2019-12-01

4. A Dose–Response Study to Examine the Methodology for Demonstrating the Local Therapeutic Equivalence of the Fluticasone Propionate Component of an Orally Inhaled Combination Therapy of Fluticasone Propionate/Salmeterol Dry Powder;Journal of Aerosol Medicine and Pulmonary Drug Delivery;2019-12-01

5. Randomized, Double-Blind, Crossover, Clinical-End-Point Pilot Study to Examine the Use of Exhaled Nitric Oxide as a Bioassay for Dose Separation of Inhaled Fluticasone Propionate;The Journal of Clinical Pharmacology;2017-11-28